COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2

NCT05075538 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

152

Enrollment

OTHER

Sponsor class

Stopped The population as defined by the inclusion/exclusion criteria and the study logistics were leading to a poor recruitment over the past years.

Conditions

Cancer

Interventions

BIOLOGICAL: Spikevax
BIOLOGICAL: Comirnaty
BIOLOGICAL: Spikevax bivalent Original/Omicron BA.1
BIOLOGICAL: Spikevax bivalent Original/Omicron BA.4-5
BIOLOGICAL: Comirnaty Original/Omicron BA.1
BIOLOGICAL: Comirnaty Original/Omicron BA.4-5
BIOLOGICAL: Comirnaty Omicron XBB.1.5
BIOLOGICAL: Spikevax Omicron XBB.1.5

Sponsor

Jules Bordet Institute

Collaborators

[object Object]